|Bid||140.05 x 300|
|Ask||141.95 x 200|
|Day's Range||139.83 - 141.17|
|52 Week Range||110.76 - 144.35|
|PE Ratio (TTM)||24.55|
|Earnings Date||Jan 23, 2018|
|Forward Dividend & Yield||3.36 (2.40%)|
|1y Target Est||146.00|
Lilly's (LLY) gastric cancer drug, Cyramza, meets primary endpoint of progression free survival in a phase III study in first-line advanced gastric cancer patients. However, it failed to improve overall survival.
Johnson & Johnson and Bayer were recently ordered by a Philadelphia court to pay $28 million in damages to an Indiana couple, related to internal bleeding about which the companies did not sufficiently warn patients.
Sanofi (SNY) starts two new phase III studies evaluating isatuximab in combination with other cancer medicines for the treatment of multiple myeloma, a rare blood cancer.
FDA approval for Novo Nordisk's (NVO) type II diabetes drug, a second indication for Lilly's Taltz, and the approval of the first Herceptin biosimilar were the key highlights this week.
Roche (RHHBY) announced interim results from the phase III IMpower150 study of Tecentriq and Avastin plus chemotherapy in people with advanced form of lung cancer.
The stakes are high as Johnson & Johnson seeks an appeals-court ruling tossing out a $151 million judgment over its Pinnacle artificial hips in a case that could foreshadow the outcome for thousands of ...